MarginsXMarginsX
Home › Canada › TSX stocks › MSCL

Satellos Bioscience Inc. (TSX: MSCL)

MSCL trades on the Toronto Stock Exchange in Life Sciences, headquartered in Ontario. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.

Close · November 13, 2026
C$9.50
-0.73% on the day
Market cap (C$)
C$202.4M
TMX list, October 31, 2026
Market cap (US$)
US$142.0M
Micro cap at 1.4257 C$/US$
1-year return
+14.7%
+19.9% year to date

Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of October 31, 2026. US$ figures convert C$ at 1.4257 C$ per US$, the Bank of Canada daily rate for November 13, 2026. Close and returns: Yahoo Finance daily closes for MSCL.TO, last bar 2026-11-13, computed by MarginsX. Website: sociallinks: 40-F text ("our website").

Profile

FieldValue
TickerMSCL on the Toronto Stock Exchange
Yahoo symbolMSCL.TO
SectorLife Sciences
HeadquartersOntario
Listed2024-02-15
Listing typeTSXV Grad
Shares outstanding21,216,439
Also listed onNasdaqGM
Index membershipNot in an S&P/TSX index per the TMX list
SEC CIK0001421642
Websitewww.satellos.com
US listingMSLE

Returns

WindowReturn
1 day-0.7%
1 week-6.1%
1 month-4.0%
3 months-31.4%
6 months-4.2%
Year to date+19.9%
1 year+14.7%
From 52-week high-46.8%
52-week rangeC$7.80 to C$17.85

Links

SEDAR+ is linked for searching only; nothing on this page is taken from it.

Recent Canadian filings by type

84 documents in 13 types. Each title links to the document at its source.

Annual financial statements (2)

DocumentTypeFiled
Financial Statements Request FormAnnual financial statements (6-K)2026-05-20
Audited Consolidated Financial Statements of the Registrant as of and for the years ended December 31, 2025 and 2024.
Period 2025-12-31
Annual financial statements (40-F)2026-03-27

Interim financial statements (3)

MD&A (4)

Annual information form (1)

DocumentTypeFiled
Annual Information Form of the Registrant for the fiscal year ended December 31, 2025.
Period 2025-12-31
Annual information form (40-F)2026-03-27

Material change report (1)

DocumentTypeFiled
Material Change report dated February 13, 2026Material change report (6-K)2026-02-17

News release (29)

DocumentTypeFiled
Press Release dated November 12, 2026News release (6-K)2026-11-12
PRESS RELEASENews release (6-K)2026-11-06
PRESS RELEASENews release (6-K)2026-11-05
PRESS RELEASENews release (6-K)2026-10-27

Management information circular / proxy (3)

DocumentTypeFiled
Management Information Circular and Notice ofManagement information circular (6-K)2026-05-20
Form of ProxyForm of proxy / voting instruction (6-K)2026-05-20
Voting Instruction FormForm of proxy / voting instruction (6-K)2026-05-20

Report of voting results (1)

DocumentTypeFiled
Report of Voting ResultsReport of voting results (6-K)2026-06-17

Prospectus (4)

DocumentTypeFiled
F-10Prospectus (short form) (F-10)2026-08-11
F-10Prospectus (short form) (F-10)2026-02-05
SUPPLProspectus supplement (SUPPL)2026-08-14
SUPPLProspectus supplement (SUPPL)2026-02-06

Annual report (1)

DocumentTypeFiled
40-F
Period 2025-12-31
Annual report (40-F) (40-F)2026-03-27

Early warning / ownership (2)

DocumentTypeFiled
Schedule 13GSchedule 13G (SCHEDULE 13G)2026-05-15
Schedule 13GSchedule 13G (SCHEDULE 13G)2026-05-12

Certification (10)

DocumentTypeFiled
Form 52-109F2 Certification of Interim Filings by CEOCertification (52-109F2) (6-K)2026-11-12
Form 52-109F2 Certification of Interim Filings by CFOCertification (52-109F2) (6-K)2026-11-12
Form 52-109F2 Certification of Interim Filings by CEOCertification (52-109F2) (6-K)2026-08-13
Form 52-109F2 Certification of Interim Filings by CFOCertification (52-109F2) (6-K)2026-08-13

Other (23)

DocumentTypeFiled
Investor Call PresentationInvestor presentation (6-K)2026-07-08
EXHIBIT 5.1Consent (F-10)2026-08-11
Consent of Independent Registered Public Accounting Firm – PricewaterhouseCoopers LLP
Period 2025-12-31
Consent (40-F)2026-03-27
EXHIBIT 5.1Consent (F-10)2026-02-05

Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.

Trading halts

Trading: the last notice, on 2026-02-06, was a resumption.

NoticeActionReasonNotice
2026-02-06 9:00 AM ETResumptionNo reason statedCIRO notice
2026-02-06 8:38 AM ETHaltDisseminationCIRO notice

Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.

Upcoming events

No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.

Recent

DateTimeEventWebcastSource
2026-11-12No time in the announcementQ1 2027 earnings releaseNo webcast link announcedSEC filing
2026-11-068:00 a.m. ETQ1 2027 earnings callWebcastSEC filing
2026-11-068:00 a.m. ETConference call
Corporate event
No webcast link announcedSEC filing

Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.

US private placements (SEC Form D)

FiledSecuritiesSoldOfferedFiling
2025-01-03Equity, Option To Acquire, Security To Be AcquiredUS$25.0MUS$25.0MSEC EDGAR
2023-05-25Equity, Option To Acquire, Security To Be AcquiredUS$33.3MUS$33.3MSEC EDGAR
2022-09-27Equity, Option To Acquire, Security To Be Acquired, OtherUS$99KUS$2.1MSEC EDGAR
2019-09-10Equity, Option To Acquire, Security To Be Acquired, OtherUS$188KUS$2.5MSEC EDGAR
2019-03-08Equity, Option To Acquire, Security To Be Acquired, OtherUS$152KUS$972KSEC EDGAR

Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.

Peers in Life Sciences

TickerCompanyExchangeMarket cap (C$)1 month1 year
AIDXHealWELL AI Inc.TSXC$201.6M-16.7%-49.6%
TSNDTerrAscend Corp.TSXC$204.1M-20.6%-36.5%
LOVECannara Biotech Inc.TSXC$198.5M-3.8%+23.0%
CRDLCardiol Therapeutics Inc.TSXC$197.0M-14.0%0.0%
RXBioSyent Inc.TSXVC$195.0M+11.4%+63.2%

The app has the price chart, every filing, private raises and the full peer set for MSCL.

Open in the app